Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07030322Enrolling By Invitation

Health and Financial Impact on the Use of a Personal Exoskeleton in the Home and Community: a Case Study

Role: lead

NCT02132702Not ApplicableCompleted

Performance Attributes and User Progression While Using Ekso

Role: lead

NCT02943915Not ApplicableCompleted

The WISE Trial - Walking Improvement for SCI With Exoskeleton

Role: lead

NCT02566850Not ApplicableTerminated

Investigational Study of the Ekso for High-Dosage Use by Individuals With SCI in a Non-Clinical Environment

Role: lead

NCT03355755Not ApplicableCompleted

Exoskeleton Treatment of Deconditioning Due to Limited Ambulation Caused by Illness or Injury

Role: lead

All 5 trials loaded